HomeHHMI's BioInteractiveGleevec Inhibits Cancer-Causing Kinase BCR-ABL

BioInteractive

Free Resources for Science Education

 
Animation
Gleevec Inhibits Cancer-Causing Kinase BCR-ABL

The drug Gleevec binds to and inactivates BCR-ABL, a mutant kinase that causes chronic myeloid leukemia. 

Awards

  • 2014 BioCommunications Association Medical Education Award, Motion Media Division

Download this item

HD (MP4)
52 MB
HD (WMV)
104 MB
SD (MP4)
27 MB
SD (WMV)
27 MB

Related Scientists

Investigator

Additional Materials

Bulletin Article
Bulletin Article